Treatment of chronic wounds represents a challenge for both the patient and modern healthcare systemsHow it works
To produce a durable closure for hard-to-heal wounds.
Treatment is non-invasive and requires minimal staff supervision.
Healing of chronic wounds significantly decreases the financial burden of modern health care.
The underlying mechanism of action can be applied to different pathological conditions.
*The COMS® One therapy system is not cleared in the US.
We are a young company founded and based in Zurich, Switzerland since 2016. The Piomic family consists of biologists, engineers, entrepreneurs, designers, seniors and a broad group of supporters. Staffed with experts from different backgrounds and a common goal: By developing a therapy which is safe and effective, we want to set a better future for patients in need.More about us
In order to maximize our global impact, we are looking for investors who share our vision and wish to shape the future of wound care with us.Information for investors
21 Jun 2022
In a multicentre clinical trial COMS® therapy significantly reduced the time to wound closure for hard-to-heal wounds when compared with Standard of Care (SOC) aloneRead more
21 Jun 2022
Piomic selected as groundbreaking Swiss start-up innovationRead more
24 Nov 2021
Dr. Jürg Traber and Maria Signer from Venenklinik Bellevue shared their experience about the advantages of COMS® Therapy at the 20th SAfW Symposium.Read more